Medical Developments International Lifts Cash Flow on Strong Penthrox Demand

Medical Developments International Limited ( (AU:MVP) ) has provided an update.

Medical Developments International reported group revenue of $10.5 million for the March quarter and $32.1 million year-to-date, driven by strong growth in its Pain Management segment and higher Penthrox volumes in Australia and Europe. The company delivered positive free cash flow, ended the quarter with $18.7 million in cash, and offset softer demand in its Respiratory segment through increased hospital and partner sales of Penthrox, while preparing for European paediatric label approvals and further penetration of emergency care markets.

Management highlighted a 26% rise in Australian hospital Penthrox volumes and 19% in-market growth in Europe, supported by pricing gains, expanded prescriber access via the PBS, and favorable health economic data showing cost savings in emergency departments. Although seasonally weaker respiratory demand and potential supply chain disruptions from Middle East tensions may weigh on second-half earnings, these impacts are expected to be limited, underlining Penthrox’s central role in the company’s growth and strategic positioning.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

More about Medical Developments International Limited

Medical Developments International Limited is an Australian healthcare company listed on the ASX that specialises in pain management and respiratory products. Its flagship product is Penthrox, an inhaled analgesic used for acute pain relief, with a growing focus on hospital and emergency department use in Australia and expanding markets in Europe.

Average Trading Volume: 107,820

Technical Sentiment Signal: Sell

Current Market Cap: A$43.37M

For detailed information about MVP stock, go to TipRanks’ Stock Analysis page.